Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs

István Tombácz(University of Pennsylvania), Dorottya Laczkó(University of Pennsylvania), Hamna Shahnawaz(University of Pennsylvania), Hiromi Muramatsu(University of Pennsylvania), Ambika Natesan(University of Pennsylvania), Amir Yadegari(University of Pennsylvania), Tyler E. Papp(University of Pennsylvania), Mohamad‐Gabriel Alameh(University of Pennsylvania), Vladimir V. Shuvaev(University of Pennsylvania), Barbara L. Mui(Acuitas Therapeutics (Canada)), Ying K. Tam(Acuitas Therapeutics (Canada)), Vladimir R. Muzykantov(University of Pennsylvania), Norbert Pardi(University of Pennsylvania), Drew Weissman(University of Pennsylvania), Hamideh Parhiz(University of Pennsylvania)
Molecular Therapy
June 4, 2021
10.1016/j.ymthe.2021.06.004
Cited by 265Open Access
Full Text

Abstract

Related Papers

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Katalin Karikó, Michael Buckstein, Houping Ni et al.|Immunity|2005|2.6k
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Karikó, Hiromi Muramatsu, Frank A. Welsh et al.|Molecular Therapy|2008|1.8k
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames, Marc Van Regenmortel, Étienne Weiss et al.|British Journal of Pharmacology|2009|1.4k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui et al.|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc, William Querbes, Soma De et al.|Molecular Therapy|2010|1.2k